Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Infections

Heart and Blood Diseases

Rare Diseases

Syndrome

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Preleukemia

Myelodysplastic Syndromes

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Lymphoma, Follicular

Lymphoma, B-Cell, Marginal Zone

Myeloproliferative Disorders

Leukemia, Prolymphocytic

Primary Myelofibrosis

Burkitt Lymphoma

Anemia, Refractory, with Excess of Blasts

Hematologic Diseases

Leukemia, Plasma Cell

Leukemia, Biphenotypic, Acute

Anemia

Anemia, Refractory

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Bone Marrow Diseases

Precancerous Conditions

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Lymphoma, B-Cell

Communicable Diseases

Epstein-Barr Virus Infections

Virus Diseases

Herpesviridae Infections

DNA Virus Infections

Tumor Virus Infections

Multiple Myeloma

Neoplasms, Plasma Cell

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Chronic Graft Versus Host Disease

Lymphosarcoma

Peripheral T-cell Lymphoma

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

Follicular Lymphoma

Marginal Zone Lymphoma

Acute Graft Versus Host Disease

Chronic Myeloproliferative Disorders

Acute Leukemia of Ambiguous Lineage

Myelodysplastic Syndrome With Excess Blasts

Plasma Cell Leukemia

B-cell Lymphoma

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Anti-Infective Agents

Central Nervous System Depressants

Other Dietary Supplements

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Mycophenolic Acid

Sirolimus

Benzocaine

Allopurinol

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Antimetabolites

Anti-Bacterial Agents

Antibiotics, Antitubercular

Antitubercular Agents

Enzyme Inhibitors

Clotrimazole

Miconazole

Antifungal Agents

Antioxidants

Protective Agents

Tannic Acid

On day 0, a target dose of 5 x 106 CD34 cells/kg will be infused.

Peripheral Blood Stem Cell Transplant

300 mg/day from day -7 to day 0. Allopurinol 150mg/m2/day for pediatric participants.

Allopurinol 300 MG

30 mg/m2 IV over 1 hour. Administered on day -6 to day -2.

Administered as a 2 hour IV infusion on day -6, +3, and +4.

On day 0, a target dose of 3 x 108 nucleated cells/kg recipient weight will be infused.

Bone Marrow Cell Transplant

The dose of TBI will be 200 cGy given in a single fraction on day -1.

Total Body Irradiation

All participants begin +5 to day +100.

Loading dose on day +5 of 5 mg/m2/day orally once (max dose of 8 mg).

Maintenance dose 2.5 mg/m2 orally daily to maintain a level of 8-12 ng/ml (max dose of 4 mg).

Sirolimus Pill

All patients begin day +5 through day +35.

3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (maximum of 1 gram per dose) every 8 hours.

Mycophenolate Mofetil

Mark Juckett

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.

Allo HSCT Using RIC and PTCy for Hematological Diseases

Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Number of participants with GVHD grades 2-4 after one year post transplant.

Number of participants with chronic GVHD after one year post transplant.

Number of participants that experienced relapse within 100 days of treatment.

Observe overall participant survival at Day 100 and at 1 and 3 years

Number of participants with transplant related mortality within 12 months of treatment.

Masonic Cancer Center, University of Minnesota

Spots Global Cancer Trial Database for sirolimus pill